(The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive. Reading time 2 minutes To treat acute pain, doctors in the U ...
A sweeping review of previous research suggests commonly prescribed opioids often provide only modest pain relief and may increase side effect risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results